Wei Chen1, Lei Zhu1, Xiaozhou Yu1, Qiang Fu1, Wengui Xu2, Ping Wang3. 1. Department of Molecular Imaging and Nuclear Medicine Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy Tianjin, China. 2. Department of Molecular Imaging and Nuclear Medicine Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy Tianjin, China. 3. Department of Molecular Imaging and Nuclear Medicine and Radiation Oncology Tianjin Medical University Cancer Institute and Hospital; Key Laboratory of Cancer Prevention and Therapy Tianjin, China.
Abstract
PURPOSE: We aimed to quantitatively evaluate volumetric metabolic tumor burden including metabolic tumor volume and total lesion glycolysis in different molecular subtypes of breast cancer using 18F-fluorodeoxyglucose (FDG) positron emission tomography/ computed tomography (PET/CT). METHODS: This study involved 99 female patients with pathologic diagnosis of primary breast cancer, who underwent 18F-FDG PET/CT before any therapy. Patients were divided into subtypes of luminal A, luminal B, ERBB2+, and basal-like based on the immunohistochemistry results. Metabolic tumor volume (MTV) and total lesion glycolysis (TLG) before and after correction for lean body mass were achieved and compared. Correlations between metabolic tumor burden and Ki-67 were analyzed and diagnostic performances of volumetric metabolic parameters were evaluated. RESULTS: TLG values were significantly different between each molecular subtype, while MTV values were not. Values of TLG were significantly reduced after normalizing for lean body mass in each subtype. Both of them showed correlations with Ki-67 and presented high diagnostic ability in identifying patients with basal-like breast cancer from the rest. TLGs before and after normalizing for the lean body mass had similar diagnostic performances in differentiating patients of basal-like subtype from the rest. CONCLUSION: Metabolic tumor burden could comprehensively reflect tumor metabolic differences of molecular subtypes of breast cancer, and it can serve to help differentiate patients with basal-like breast cancer.
PURPOSE: We aimed to quantitatively evaluate volumetric metabolic tumor burden including metabolic tumor volume and total lesion glycolysis in different molecular subtypes of breast cancer using 18F-fluorodeoxyglucose (FDG) positron emission tomography/ computed tomography (PET/CT). METHODS: This study involved 99 female patients with pathologic diagnosis of primary breast cancer, who underwent 18F-FDG PET/CT before any therapy. Patients were divided into subtypes of luminal A, luminal B, ERBB2+, and basal-like based on the immunohistochemistry results. Metabolic tumor volume (MTV) and total lesion glycolysis (TLG) before and after correction for lean body mass were achieved and compared. Correlations between metabolic tumor burden and Ki-67 were analyzed and diagnostic performances of volumetric metabolic parameters were evaluated. RESULTS: TLG values were significantly different between each molecular subtype, while MTV values were not. Values of TLG were significantly reduced after normalizing for lean body mass in each subtype. Both of them showed correlations with Ki-67 and presented high diagnostic ability in identifying patients with basal-like breast cancer from the rest. TLGs before and after normalizing for the lean body mass had similar diagnostic performances in differentiating patients of basal-like subtype from the rest. CONCLUSION:Metabolic tumor burden could comprehensively reflect tumor metabolic differences of molecular subtypes of breast cancer, and it can serve to help differentiate patients with basal-like breast cancer.
Authors: Irene A Burger; Dominic M Huser; Cyrill Burger; Gustav K von Schulthess; Alfred Buck Journal: Nucl Med Biol Date: 2012-03-03 Impact factor: 2.408
Authors: Hye Ryoung Koo; Jeong Seon Park; Keon Wook Kang; Nariya Cho; Jung Min Chang; Min Sun Bae; Won Hwa Kim; Su Hyun Lee; Mi Young Kim; Jin You Kim; Mirinae Seo; Woo Kyung Moon Journal: Eur Radiol Date: 2013-10-05 Impact factor: 5.315
Authors: Ana María García Vicente; Ángel Soriano Castrejón; Alberto León Martín; Ignacio Chacón López-Muñiz; Vicente Muñoz Madero; María del Mar Muñoz Sánchez; Azahara Palomar Muñoz; Ruth Espinosa Aunión; Ana González Ageitos Journal: Eur J Nucl Med Mol Imaging Date: 2013-04-30 Impact factor: 9.236
Authors: Antonio C Wolff; M Elizabeth H Hammond; David G Hicks; Mitch Dowsett; Lisa M McShane; Kimberly H Allison; Donald C Allred; John M S Bartlett; Michael Bilous; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Pamela B Mangu; Soonmyung Paik; Edith A Perez; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Daniel F Hayes Journal: Arch Pathol Lab Med Date: 2013-10-07 Impact factor: 5.534
Authors: Bing Dong; Xiaoxing Yin; Han Xu; Kun Zhou; Longzhi Li; Baoxing Tian; Rongrong Cui Journal: Am J Transl Res Date: 2022-04-15 Impact factor: 3.940